Abeona Therapeutics Inc. (NASDAQ:ABEO) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $19.11 and last traded at $19.13, with a volume of 1,086,318 shares trading hands. The stock had previously closed at $17.50.
Several equities research analysts recently issued reports on ABEO shares. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a report on Thursday, August 24th. BidaskClub downgraded Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 27th. Cantor Fitzgerald set a $21.00 price objective on Abeona Therapeutics and gave the company a “buy” rating in a report on Tuesday, July 18th. Maxim Group reiterated a “buy” rating and issued a $17.00 price objective (up previously from $14.00) on shares of Abeona Therapeutics in a report on Tuesday, July 18th. Finally, Zacks Investment Research upgraded Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $21.44.
The stock’s market cap is $779.55 million. The stock’s 50 day moving average is $14.91 and its 200-day moving average is $8.57.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). Abeona Therapeutics had a negative net margin of 2,746.38% and a negative return on equity of 26.66%. The firm had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.21 million. Analysts forecast that Abeona Therapeutics Inc. will post ($0.68) earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Abeona Therapeutics by 11.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock valued at $6,922,000 after acquiring an additional 108,730 shares during the period. Highbridge Capital Management LLC grew its position in shares of Abeona Therapeutics by 23.5% in the 1st quarter. Highbridge Capital Management LLC now owns 681,611 shares of the biopharmaceutical company’s stock valued at $3,408,000 after acquiring an additional 129,811 shares during the period. State Street Corp bought a new position in shares of Abeona Therapeutics in the 2nd quarter valued at about $1,900,000. Northern Trust Corp grew its position in shares of Abeona Therapeutics by 406.3% in the 2nd quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock valued at $1,649,000 after acquiring an additional 206,775 shares during the period. Finally, Wellington Management Group LLP grew its position in shares of Abeona Therapeutics by 17.4% in the 1st quarter. Wellington Management Group LLP now owns 204,590 shares of the biopharmaceutical company’s stock valued at $1,023,000 after acquiring an additional 30,300 shares during the period. 38.38% of the stock is owned by institutional investors.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.